Effect of furosemid versus placebo on quality of life in hypertensive patients with pulmonary edema

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN93135084

Enrollment

Registered

2006-08-03

Start date

2006-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive pulmonary edema Respiratory Hypertensive pulmonary edema

Interventions

Intravenous furosemide versus intravenous placebo on top of standard medication.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hypertensive pulmonary edema (Relative Risk [RR] more than 180 mmHg, crackles in auscultation) 2. Over 18 years of age

Exclusion criteria

Exclusion criteria: 1. Women of childbearing potential 2. Chronic renal failure with renal replacement therapy 3. Acute ST-Elevation Myocardial Infarction (STEMI) 4. Need for intubation on arrival at scene 5. Need for catecholamines on arrival 6. Known incompatibilities to furosemide, urapidil or morphine hydrochloride

Design outcomes

Primary

Measure	Time frame
Changes in dyspnoea severity one hour after hospital admission (BORG scale).	—

Secondary

Measure	Time frame
1. BORG scale at hours two, three and six 2. Visual analogue scale score at one, two, three and six hours 3. Blood pressure 4. Partial pressure of oxygen in arterial blood (paO2), partial pressure of carbon dioxide in arterial blood (paCO2), spot oxygen saturation (SpO2) 5. pH, BE, lactate 6. Safety: acute myocardial infarction, hypotension, intubation, catecholamines, cardiac arrest, death	—

Countries

Austria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026